Additive Intraocular Pressure-Lowering Effects of a Novel Selective EP2 Receptor Agonist, Omidenepag Isopropyl, Combined with Existing Antiglaucoma Agents in Conscious Ocular Normotensive Monkeys
Fuwa M., Shimazaki A., Odani-Kawabata N., Kirihara T., Taniguchi T., Iwamura R., Yoneda K., Kato M., Morishima K., Shams N.K.
View publication
-
Therapeutic Area
Glaucoma
-
Categories
Preclinical development
-
Affiliations
Fuwa, M., Product Development Division, Santen Pharmaceutical Co. Ltd., Nara, Japan; Shimazaki, A., Product Development Division, Santen Pharmaceutical Co. Ltd., Nara, Japan; Odani-Kawabata, N., Product Development Division, Santen Pharmaceutical Co. Ltd., Nara, Japan, Product Development Division, Santen Inc., Emeryville, CA, United States; Kirihara, T., Ophthalmology Innovation Center, Santen Pharmaceutical Co. Ltd., Osaka, Japan; Taniguchi, T., Ophthalmology Innovation Center, Santen Pharmaceutical Co. Ltd., Osaka, Japan; Iwamura, R., Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan; Yoneda, K., Pharmaceuticals Research Laboratory, Pharmaceutical Division, Ube Industries, Ltd., Yamaguchi, Japan; Kato, M., Product Development Division, Santen Pharmaceutical Co. Ltd., Nara, Japan; Morishima, K., Product Development Division, Santen Pharmaceutical Co. Ltd., Nara, Japan; Shams, N.K., Product Development Division, Santen Inc., Emeryville, CA, United States, Ophthalmology Innovation Center, Santen Inc., Emeryville, CA, United States